Investigation in Progress — No Complaint Filed Yet
BG&G is actively investigating potential securities fraud claims against Fulcrum Therapeutics, Inc.. If a complaint is filed, this page will be updated. Investors are encouraged to contact us now to preserve their rights.
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fulcrum Therapeutics, Inc. (“Fulcrum” or “the Company”) (NASDAQ: FULC). Investors who purchased Fulcrum securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Fulcrum has violated federal securities laws.
Fulcrum Investigation Details
On June 1, 2026, Fulcrum disclosed in a Form 8-K that feedback from the U.S. Food and Drug Administration raised concerns regarding a potential malignancy risk associated with PRC2 inhibition. The Company also announced it was discontinuing development of its lead candidate, pociredir, and initiating a strategic review of its business. Following this news, Fulcrum’s stock price dropped before the next trading session opened.
What’s Next for Fulcrum Investors?
If you are aware of any facts relating to this investigation or purchased Fulcrum securities, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911
FULC — Stock Performance
About Bronstein, Gewirtz & Grossman, LLC
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace.”